Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety, tolerability, pharmacokinetics and efficacy of twice-daily AP611074 5% gel in condyloma patients over up to 16 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Condyloma Acuminatum

Drugs mentioned

• AP611074 5% Gel (AP611074)

Snippet

Sponsor: Vaxart | Conditions: Condyloma | Phase 2 | Status: COMPLETED